Thermo Fisher Scientific is the largest life sciences tools and services company in the world, supplying pharmaceutical companies, biotech firms, hospitals, academic institutions, and government labs with essentially everything they need to conduct research, develop drugs, run clinical trials, and manufacture therapies. Thermo Fisher operates across four segments: Life Sciences Solutions (reagents, consumables, and instruments for biological research and biologics manufacturing), Analytical Instruments (mass spectrometry, electron microscopy, and chemical analysis tools), Specialty Diagnostics (test kits and reagents for clinical and healthcare labs), and Laboratory Products and Biopharma Services (the largest segment, combining broad lab distribution with contract drug development and manufacturing). The Biopharma Services business includes Patheon, a CDMO providing drug substance and fill-finish manufacturing, and PPD, a CRO managing clinical trials — together making Thermo Fisher one of the largest players in both categories globally. Thermo Fisher's revenue mix combines recurring consumables and reagents, which provide stability, with instrument sales, which are more cyclical, and long-term CDMO and CRO service contracts. The company invests roughly 7% of manufacturing revenue in R&D and uses its PPI continuous improvement system to drive productivity gains. M&A is a core part of Thermo Fisher's strategy, with recent deals including the Solventum filtration business and the announced acquisition of Clario, a clinical trial data solutions company.